MAINTOBA INFLUENZA STUDY

曼托巴流感研究

• 批准号: 3120921
• 负责人: DAVID S. FEDSON
• 金额: $ 15.59万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-03-07 至 1993-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3120921
• 关键词: communicable disease control; disease /disorder proneness /risk; drug adverse effect; drug quality /standard; epidemiology; health care service utilization; health science profession; human morbidity; human mortality; human therapy evaluation; immunization; influenza; influenza vaccines; longitudinal human study; medical complication; outpatient care; patient care; pneumonia; statistics /biometry

Influenza continues to cause significant morbidity and mortality. In spite of strong recommendations from expert advisory groups, influenza vaccine is not widely used. Reasons for this include (1) difficulty in identifying high-risk patients; (2) uncertainty about the long-term health benefits to patients who are vaccinated. Also, little is known about patterns of use of influenza vaccine. The Manitoba Influenza Study will address each of these questions. This four-year project will use a person-oriented linked record derived from claims data gathered by the Manitoba Health Services Commission (MHSC) for the period 1980-86. The linked record includes demographic data on MHSC enrollees and physicians, influenza vaccinations. Two influenza outbreak periods (1982-83 and 1985-86) will be studied. Five studies will be undertaken: Study 1 will examine the natural history of high-risk conditions to identify factors associated with increased risk of ambulatory care visits, hospitalization, and death due to respiratory conditions during outbreak periods. It will also identify missed opportunities for vaccination. Study 2 will use both retrospective cohort and case-control methods to assess the clinical effectiveness of influenza vaccination in preventing influenza-related ambulatory care visits, hospitalizations, and deaths. Study 3 patient receipt of vaccine. Study 4 will assess known and hitherto unknown adverse effects of influenza vaccination serious enough to require medical care within 3, 7, 14 and 28 days of vaccination. Study 5 will assess the long-term (five-year) outcomes of patients who have had and have not had hospital care for influenza-related illness to determine whether of not "pneumonia is the old man's friend". The Manitoba Influenza Study will provide new information on the clinical effectiveness of influenza vaccination, its safety, and its long-term health benefits. It will characterize patterns of vaccine use and suggest new policies and strategies for influenza vaccination for both the United States and Canada.

流感继续造成显着的发病率和死亡率。 尽管 在专家咨询小组的强烈建议中，流感疫苗是 没有广泛使用。 其原因包括（1）识别困难 高危患者； (2) 长期健康益处的不确定性 接种疫苗的患者。 此外，人们对使用模式知之甚少 流感疫苗。 马尼托巴省流感研究将解决这些问题。 这 为期四年的项目将使用源自以下内容的以人为本的链接记录： 马尼托巴省卫生服务委员会 (MHSC) 收集的索赔数据 1980-86 年期间。 链接的记录包括 MHSC 的人口统计数据 参与者和医生，流感疫苗接种。 两次流感爆发 将研究两个时期（1982-83 年和 1985-86 年）。 五项研究将 进行：研究 1 将检查高风险的自然史 确定与流动性风险增加相关的因素的条件 因呼吸系统疾病而就诊、住院和死亡 爆发期间。 它还将识别错失的机会 疫苗接种。 研究2将使用回顾性队列和病例对照 评估流感疫苗接种临床效果的方法 预防与流感相关的门诊就诊、住院治疗和 死亡人数。 研究 3 患者接受疫苗。 研究 4 将评估已知和 迄今为止未知的流感疫苗副作用严重到足以 接种疫苗后 3、7、14 和 28 天内需要医疗护理。 研究5 将评估已经接受过治疗的患者的长期（五年）结果 尚未接受流感相关疾病的医院护理来确定 是否“肺炎是老人的朋友”。 马尼托巴流感研究将提供有关临床的新信息 流感疫苗接种的有效性、安全性和长期性 健康益处。 它将描述疫苗使用模式的特征并提出建议 联合国流感疫苗接种新政策和战略 美国和加拿大。